Clinical Trials

Lymphoma of the liver

Displaying 2 studies

  • A Study of Tumor Markers to Assess Risk of Recurrence of Liver Cancer After a Liver Transplant Jacksonville, FL

    The purpose of this study is evaluation of tumoral markers at the time of transplant to assess recurrence risk, and assessment of tumor sensitivity to a panel of candidate therapeutics as a guide to adjunct or therapeutic therapies for recurrent hepatocellular cancers (HCC).  

  • Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Rochester, MN

    RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Lenalidomide may stop the growth of cancer cells by blocking blood flow to the cancer. Giving everolimus together with lenalidomide may be an effective treatment for lymphoma.

    PURPOSE: This phase I/II trial is studying the side effects and best dose of giving everolimus and lenalidomide together and to see how well they work in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma.

.

Mayo Clinic Footer